Scan how Elanco Animal Health’s latest guidance compares with peers by reviewing a curated set of list of solid balance sheet and fundamentals (24 results) in similar quality-focused territory.
To own Elanco Animal Health, you need to be comfortable with a story built on new product adoption, higher margin biologics and steady balance sheet repair, as laid out in the analyst consensus Narrative on Simply Wall St. The fresh third quarter profit and slightly higher 2026 revenue guidance support that thesis, but foreign exchange and farm animal demand still matter a lot in the next year.
The biggest near term catalyst remains execution on the Big 6 portfolio and wider pet and farm franchises converting into cleaner earnings and cash flow. The main risk is that pricing pressure, swine market volatility or currency moves offset the revenue guidance raise, leaving limited progress on margins even if the top line stays within the updated range.
The raised 2026 revenue guidance to US$5,155 million to US$5,180 million is the announcement that ties closest to this story. It links directly to earlier expectations for mid single digit organic growth and higher innovation revenue, and gives investors a firmer near term reference point for how the pipeline is translating into reported sales.
For catalysts, that guidance bracket now becomes the operational yardstick against which Elanco Animal Health will be judged over the next few quarters. Any stretch in foreign exchange headwinds, persistent pressure in Asian swine or slower uptake of higher margin biologics would quickly test how resilient that outlook is and how much flexibility the Ascend productivity program really offers.
Elanco Animal Health’s current earnings are a loss of US$199.0 million, with analysts expecting earnings of US$288.5 million by 2029. This implies an earnings swing of roughly US$487.5 million. That outlook is tied to an assumed 4.9% yearly increase in revenue, which is expected to take sales to about US$5.8 billion in 2029.
Uncover why Elanco Animal Health's fair value indicates a 13% potential upside to its current price that may not last much longer.
One bullish angle on Elanco Animal Health leans heavily on the Elwood biologics expansion and Ascend cost savings. Those analysts were penciling in revenue of about US$6.1b and earnings of roughly US$447.7 million by 2029, far above consensus. You can treat this guidance update as a fresh test of that more optimistic script.
Explore 3 other Elanco Animal Health fair value estimates, including one that suggests a potential 66% increase from the current price.
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
Once you have a view on Elanco Animal Health, it often helps to line that thesis up against a broader watchlist. The Simply Wall St Screener can surface other companies with very different profiles, so you can see where Elanco fits in your wider plan.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com